
## Cédric Garcia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7930989/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood, 2014, 124, 3991-3995.	1.4	265
2	Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia, 2015, 29, 783-787.	7.2	191
3	The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood, 2009, 114, 1884-1892.	1.4	110
4	Platelets Are Critical Key Players in Sepsis. International Journal of Molecular Sciences, 2019, 20, 3494.	4.1	105
5	Thromboembolic events and Covid-19. Advances in Biological Regulation, 2020, 77, 100735.	2.3	61
6	Platelet activation and prothrombotic properties in a mouse model of peritoneal sepsis. Scientific Reports, 2018, 8, 13536.	3.3	44
7	The Sykâ€kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparinâ€PF4 complex directed antibodies. Journal of Thrombosis and Haemostasis, 2011, 9, 2067-2076.	3.8	42
8	Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. Haematologica, 2019, 104, 2292-2299.	3.5	39
9	Predictive Value of Susceptibility Vessel Sign for Arterial Recanalization and Clinical Improvement in Ischemic Stroke. Stroke, 2019, 50, 512-515.	2.0	33
10	Effect of estetrol, a selective nuclear estrogen receptor modulator, in mouse models of arterial and venous thrombosis. Molecular and Cellular Endocrinology, 2018, 477, 132-139.	3.2	28
11	Platelet activation and arterial peripheral serotonin turnover in cardiac remodeling associated to aortic stenosis. American Journal of Hematology, 2015, 90, 15-19.	4.1	26
12	Catalytic dysregulation of SHP2 leading to Noonan syndromes affects platelet signaling and functions. Blood, 2019, 134, 2304-2317.	1.4	23
13	Deciphering biased inverse agonism of cangrelor and ticagrelor at P2Y12 receptor. Cellular and Molecular Life Sciences, 2019, 76, 561-576.	5.4	20
14	Kinetics of mean platelet volume predicts mortality in patients with septic shock. PLoS ONE, 2019, 14, e0223553.	2.5	17
15	Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: Comparative effects of prasugrel and ticagrelor on platelet reactivity. International Journal of Cardiology, 2014, 174, 874-876.	1.7	15
16	Effect of chronic estradiol plus progesterone treatment on experimental arterial and venous thrombosis in mouse. PLoS ONE, 2017, 12, e0177043.	2.5	14
17	Absence of susceptibility vessel sign is associated with aspiration-resistant fibrin/platelet-rich thrombi. International Journal of Stroke, 2021, 16, 972-980.	5.9	14
18	The class I phosphoinositide 3-kinases α and β control antiphospholipid antibodies-induced platelet activation. Thrombosis and Haemostasis, 2016, 115, 1138-1146.	3.4	13

Cédric Garcia

#	Article	IF	CITATIONS
19	ATPâ€binding cassette transporter 1 (ABCA1) deficiency decreases platelet reactivity and reduces thromboxane A2 production independently of hematopoietic ABCA1. Journal of Thrombosis and Haemostasis, 2016, 14, 585-595.	3.8	12
20	Platelet activation and partial desensitization are associated with viral xenophagy in patients with severe COVID-19. Blood Advances, 2022, 6, 3884-3898.	5.2	12
21	Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity. Journal of Thrombosis and Haemostasis, 2012, 10, 1946-1949.	3.8	10
22	Acute coronary syndrome remodels the antiplatelet aggregation properties of HDL particle subclasses. Journal of Thrombosis and Haemostasis, 2018, 16, 933-945.	3.8	9
23	Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo. Journal of Thrombosis and Haemostasis, 2020, 18, 3336-3351.	3.8	8
24	Evolution of platelet activation parameters during septic shock in intensive care unit. Platelets, 2022, 33, 918-925.	2.3	7
25	First description of an IgM monoclonal antibody causing αIlbβ3 integrin activation and acquired Glanzmann thrombasthenia associated with macrothrombocytopenia. Journal of Thrombosis and Haemostasis, 2019, 17, 795-802.	3.8	6
26	Targeted drug therapy: The platelet side. Platelets, 2011, 22, 479-484.	2.3	5
27	Elucidation of Mild Bleeding Disorders Reported Under Ibrutinib (Imbruvica(R)) Therapy: Implications for Optimal Clinical Management. Blood, 2014, 124, 3296-3296.	1.4	5
28	δ-storage pool disease: an underestimated cause of unexplained bleeding. Hematologie, 2017, 23, 243-254.	0.0	4
29	Impedance-based sensors discriminate among different types of blood thrombi with very high specificity and sensitivity. Journal of NeuroInterventional Surgery, 2023, 15, 526-531.	3.3	3
30	Assessment of platelet response to clopidogrel through measurement of ADP-induced Akt phosphorylation. Journal of Thrombosis and Haemostasis, 2009, 7, 1411-1413.	3.8	2
31	Platelet function defects and sertralineâ€induced bleeding: a case report. Fundamental and Clinical Pharmacology, 2020, 34, 632-636.	1.9	2
32	Occurrence of a paroxysmal nocturnal hemoglobinuria clone in an essential thrombocythemia: a link between <i>PIGV</i> and <i>MPL</i> . Haematologica, 2022, 107, 1989-1993.	3.5	2
33	Platelet Activation Is Limited during Transcatheter Aortic Valve Implantation in Patients on Aspirin Monotherapy and without per Procedural Clinical Complications. TH Open, 2019, 03, e146-e152.	1.4	Ο